Anticancer agent 320

Anticancer agent 320 (compound 6g) (3.125-50 μM) inhibits the viability of MCF7, A549, and HCT116 cancer cells with IC₅₀ values of 0.89, 1.02 and 1.29 μM, respectively, while showing minimal toxicity to MRC-5 cells (≥100 μM)^[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) induces G1 phase arrest in HCT116 and A549 cells, and induces G2 phase accumulation in MCF7 cells^[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) induces DNA double-strand breaks in A549 and HCT116 cells, but does not significantly increase DNA damage in MCF7 cells^[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) potently induces early apoptosis in A549 cells, and modestly induces early apoptosis in HCT116 and MCF7 cells^[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) inhibits 3D spheroid growth in A549 cells and inhibits initial spheroid formation in MCF7 cells^[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) inhibits long-term colony formation in A549, HCT116, and MCF7 cells, with the greatest effect observed in HCT116 cells^[1].
Anticancer agent 320 exhibits favourable binding interactions with key cancer-related proteins, including the highest affinity for MAPK8 with a docking score of -7.872 kcal/mol and MM-GBSA binding free energy of -55.11 kcal/mol^[1].
Anticancer agent 320 reduces membrane potential in A549, HCT116, and MCF7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.